Reneuron Share Discussion Threads

[rayrac] 08/7/2019 23:32

Unseen volume somewhere Hollwood6? If Woodford has sold , then volume must be higher than we can see. Anyway, at least we know why Woodford is selling!!

[hollywood6] 08/7/2019 17:38

Volume too low

[daffodil4] 08/7/2019 17:02

If we are up today..then there is definitely a background
buyer scooping up Woodford's sells......Looking good Chaps!!!

[xow98] 08/7/2019 16:58

Woodford sold another 1.56%, down to 33.02% (circa 496k shares sold)

[pejaten] 08/7/2019 16:37

Great that the price is rising despite Woodford selling

[cashflow66] 06/7/2019 21:17

I think Scuba's Motive is pretty obvious.

[martinfrench] 06/7/2019 17:38

I think also the price has drifted a little because on the back of the fosun deal I expected maybe another territory by now which could of course still come anytime.

It would be staggering if the Chinese were acting differently to other continents but maybe they like to get in early

[martinfrench] 06/7/2019 17:26

Scuba,

Having read your post which didn't really say anything and since your not invested I can't really see your motive ?

[hollywood6] 06/7/2019 12:24

What surgery are you going to do? Read about the condition, what RENE are trying to do, what the expectations are and how they can be applied.

[hollywood6] 06/7/2019 12:22

I'm sorry but this is completely incorrect. RP patients who become completely blind are not going to have success in this trial.

[scubadiverr] 06/7/2019 10:14

Is surgery not an option? Admittedly it would be more invasive. Eyes are not my area and I may have been to quick to dismiss this. May well do some research.

[pdt] 06/7/2019 08:49

Next week is going to be interesting.

The second cohort were all recruited and treated by 8th May which means their 60 days data should be collected about now (perhaps by this weekend). They therefore will have data to compare to the 60 day data in the first cohort.

The second cohort is starting from a better baseline of visual acuity so you could argue that they may not have such a dramatic improvement as seen in the first. However, they have more intact retina to start with so potentially i hope they may have the same or even better results.

In addition the very first person treated in the first cohort will have 6 month data and the other two will have their 120 data. Other clinical news should be that they can announce that the remaining cohorts have been recruited/treated and they are on target for results at the end of the calendar year. This package of data will be presented to the FDA to determine the next step.

Any time next week or on results day would be a good time for a clinical update in my view. It is a significant milestone. It is also a good data point for a potential licencee to review.

Exciting times.

[masingi] 06/7/2019 07:11

Scubadiver
The results of the trials: it maketh the blind to see. A fairly emphatic end-point. There is no alternative treatment available.

[hollywood6] 05/7/2019 18:48

High risk high reward. Simple as that

[scubadiverr] 05/7/2019 18:36

I'm not a holder nor have I conducted proper research into the company. If I were a holder of I of course would have researched thoroughly and attempted to speak with investigators. Just wanted to see the response of this BB to the questions having read a number of posts talk only of results to a particular trial. I actually work in clinical trials so know of the high cost of developing treatments and also the high failure rate. I also know of a number of companies that have been involved in stem cells and the positive market sentiment that followed only for it to end in tears. I hope that is not the case here but don't intend to conduct proper research in view of becoming a holder. GL

[rayrac] 05/7/2019 11:44

Woodford, he’s the bug in the works!

[small crow] 05/7/2019 10:40

It's called the Bends....

[ps0u3165] 05/7/2019 09:17

scubadiverr. You should not be investing here or anywhere else for that matter if you need to ask those questions.

[esmerelda] 05/7/2019 07:38

Have you read any of the RNS? Have you looked at the RP presentation? Have you looked at the company website? Have you read the last five hundred messages to see what people are saying? It doesn't feel like it but I wish you well with your other investments.

[eggy6198] 05/7/2019 07:21

Looks like a deramp or you havnt researched the company. Currently it has 3 products all in development. Ths eye product is targeting a part of the market where there are no current treatments as alternative product only fixes very small part of eye problens and costs a million dollars i believe. Rene treatment which is 3 years away from market is aimed at around 70% of eye issues. I will leave you to look but thats billions in value. So if next results are good/great well the brakes are off.

[scubadiverr] 04/7/2019 22:09

If the trial was to show no superiority over the current gold standard where would this leave the company? Has RENE already got licences to market patented products in a number of geographical areas or is it a one trick pony whose trick has yet to be proved? Before the accusations of de-ramping follow; i'm generally interested as can see significant potential upside if marking licences obtained on good results but also a nasty fall should it not, especially without income from existing products. I guess i'm asking why is this worth 5.5 x more than it was at the beginning of March and what barriers are in place to avoid a return to that value?

[esmerelda] 04/7/2019 03:15

Surely it doesn't matter when or how we are told Hollywood? It will be good to get an update on how things are progressing. Most companies Finals include comments relating to current activities or post-period transactions.

[jensonbensonjohnson] 03/7/2019 18:19

Go away Hair Dryer

[hollywood6] 03/7/2019 17:22

Are RP results definitely coming out with the financial next week? If so, it concerns me. I really hope the RP trials continue with the positive trend

[dickbush] 02/7/2019 10:49

More on Woodford:

The company said it was making “positive progress” selling its illiquid holdings. Woodford has sold off £459m of assets since the fund was suspended, according to Citywire.

Woodford said it is close to appointing a firm to help it sell other investments. Last week Sky reported Woodford was close to appointing PTJ Park Hill.

Note: PJT is a circa $1 billion market cap US quoted company spun off from the giant Blackstone a few years ago.